FDA Memo Discussed Pulling Vioxx Based On HMO Study
An FDA internal memo discusses pulling Merck's Vioxx (rofecoxib) based on the results of a retrospective study sponsored by the agency and Kaiser Permanente
An FDA internal memo discusses pulling Merck's Vioxx (rofecoxib) based on the results of a retrospective study sponsored by the agency and Kaiser Permanente